PCV88 Long Term Cost-Effectiveness Analysis of Ticagrelor in Patients with Acute Coronary Syndromes from a Brazilian Public Healthcare perspective Based on Data from the Plato Trial

Public Healthcare ◽

Healthcare Perspective ◽

Effectiveness Analysis ◽

PCV45 Long Term Cost-Effectiveness Analysis of Ticagrelor in Patients with Acute Coronary Syndromes From a Turkish Health Care Perspective Based on Data From the Plato Trial

Value in Health ◽

10.1016/j.jval.2012.08.988 ◽

2012 ◽

Vol 15 (7) ◽

pp. A370 ◽

Cited By ~ 1

Author(s):

A. Abaci ◽

E. Bozkurt ◽

C. Mellstrom ◽

B. Caglayan

Keyword(s):

Health Care ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective

Singapore Medical Journal ◽

10.11622/smedj.2013045 ◽

2013 ◽

Vol 54 (3) ◽

pp. 169-175 ◽

Cited By ~ 10

Author(s):

CT Chin ◽

C Mellstrom ◽

TS Chua ◽

DB Matchar

Keyword(s):

Cost Effectiveness ◽

Lifetime Cost ◽

Healthcare Perspective ◽

Effectiveness Analysis ◽

The organisational value of diagnostic strategies using high-sensitivity troponin for patients with possible acute coronary syndromes: a trial-based cost-effectiveness analysis

BMJ Open ◽

10.1136/bmjopen-2016-013653 ◽

2017 ◽

Vol 7 (6) ◽

pp. e013653 ◽

Cited By ~ 12

Author(s):

Paul Jülicher ◽

Jaimi H Greenslade ◽

William A Parsonage ◽

Louise Cullen

Keyword(s):

Cost Effectiveness ◽

High Sensitivity ◽

Diagnostic Strategies ◽

Effectiveness Analysis ◽

High Sensitivity Troponin ◽

PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

Value in Health ◽

10.1016/j.jval.2018.09.622 ◽

2018 ◽

Vol 21 ◽

pp. S105

Author(s):

P. Stafylas ◽

M. Karaiskou ◽

D. Arzoumanidou ◽

N. Kolevris ◽

A. Kotsanis ◽

...

Keyword(s):

Cost Effectiveness ◽

Secondary Prevention ◽

Effectiveness Analysis ◽

Cost-Effectiveness Analysis and the Treatment of Acute Coronary Syndromes

Contemporary Cardiology - Management of Acute Coronary Syndromes ◽

10.1007/978-1-59259-731-4_25 ◽

1999 ◽

pp. 601-610

Author(s):

Harlan M. Krumholz

Keyword(s):

Cost Effectiveness ◽

Effectiveness Analysis ◽

PCV1 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN HUNGARY

Value in Health ◽

10.1016/s1098-3015(10)67413-x ◽

2005 ◽

Vol 8 (6) ◽

pp. A88

Author(s):

K Borsos ◽

B Nagy ◽

J Spiesser ◽

S Gabriel ◽

G Blaskó

Keyword(s):

Cost Effectiveness ◽

St Segment Elevation ◽

Effectiveness Analysis ◽

St Segment ◽

P3002 Cost-effectiveness analysis of clopidogrel in acute coronary syndromes without ST-segment elevation: a five European countries analysis

European Heart Journal ◽

10.1016/s0195-668x(03)95780-0 ◽

2003 ◽

Vol 24 (5) ◽

pp. 586 ◽

Cited By ~ 4

Author(s):

L ANNEMANS

Keyword(s):

Cost Effectiveness ◽

European Countries ◽

St Segment Elevation ◽

Effectiveness Analysis ◽

St Segment ◽

PCV26 Lifetime Cost-Effectiveness Analysis of Ticagrelor in Patients With Acute Coronary Syndromes Based on the Plato Trial: A Singapore Health Care Perspective

Value in Health ◽

10.1016/j.jval.2012.08.193 ◽

2012 ◽

Vol 15 (7) ◽

pp. A632-A633

Author(s):

C.T. Chin ◽

C. Mellström ◽

T.S. Chua ◽

D.B. Matchar

Keyword(s):

Health Care ◽

Cost Effectiveness ◽

Lifetime Cost ◽

Effectiveness Analysis ◽

Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts — Response to the letter to the Editor

International Journal of Cardiology ◽

10.1016/j.ijcard.2017.10.079 ◽

2018 ◽

Vol 251 ◽

pp. 33

Author(s):

Bastian Wein ◽

Christoph Kaiser

Keyword(s):

Cost Effectiveness ◽

Drug Eluting Stents ◽

Comparative Cost ◽

Effectiveness Analysis ◽

Letter To The Editor ◽

Drug Eluting ◽

Coronary Syndromes ◽

Western European

Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts

International Journal of Cardiology ◽

10.1016/j.ijcard.2017.07.102 ◽

2017 ◽

Vol 248 ◽

pp. 20-27 ◽

Cited By ~ 3

Author(s):

Bastian Wein ◽

Michael Coslovsky ◽

Reza Jabbari ◽

Søren Galatius ◽

Matthias Pfisterer ◽

...

Keyword(s):

Cost Effectiveness ◽

Drug Eluting Stents ◽

Comparative Cost ◽

Effectiveness Analysis ◽

Drug Eluting ◽

Coronary Syndromes ◽

Western European